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ABSTRACT Using various methods, e.g., spectrophotometry, circular dichroism, and isothermal titration calorimetry, the
interaction of poncean S (PS) with human serum albumin (HSA) was characterized at pH 1.81, 3.56, and 7.40 using the spectral
correction technique, and Langmuir and Temkin isothermal models. The consistency among results concerning, e.g., binding
number, binding energy, and type of binding, showed that ion pair electrostatic attraction ﬁxed the position of PS in HSA and
subsequently inducedacombinationofmultiple noncovalent bonds suchasH-bonds, hydrophobic interactions, and vanderWaals
forces. Ion pair attraction andH-bonds produced a stable PS-HSA complex and led to amarked change in the secondary structure
of HSA in acidic media. The PS-HSA binding pattern and the process of change in HSA conformation were also investigated. The
potentially toxic effect of PS on the transport function of HSA in a normal physiological environment was analyzed. This work
provides a useful experimental strategy for studying the interaction of organic substances with biomacromolecules, helping us to
understand the activity or mechanism of toxicity of an organic compound.
INTRODUCTION
Human serum albumin (HSA) is the major protein compo-
nent of blood plasma but is also found in the interstitial ﬂuid
of body tissues. In mammals, albumin is synthesized by the
liver and has a half-life of 19 days in the circulation (1,2). It
is the major contributor to the oncotic pressure of blood
plasma (3). Albumin is also reported to be chieﬂy respon-
sible for the maintenance of blood pH (4). Serum albumin
has been one of the most extensively studied proteins for the
past 40 years: its primary structure (a single-chain polypep-
tide of 585 residues) has been known for a long time, and its
tertiary structure was determined a few years ago by x-ray
crystallography (5). Its secondary structure comprises 67%
helix (six turns) and 17 disulﬁde bridges (6), including three
structurally similar a-helical domains (I–III), each divided
into subdomains A and B (7). HSA is called a multifunc-
tional plasma carrier protein because of its ability to bind an
unusually broad spectrum of ligands. These include inor-
ganic cations, organic anions, various drugs, amino acids,
and, perhaps most important, physiologically available insol-
uble endogenous compounds such as bilirubin (3), fatty
acids, and bile acids. Binding to HSA facilitates their trans-
port throughout the circulation (9).
Structural studies have mapped the locations of the fatty
acid binding sites throughout the protein (10,11). Like the
endogenous ligands, many exogenous compounds also bind
to HSA (12), for example, commonly used drugs with acidic
or electronegative features, e.g., warfarin (13), camptothe-
cins (14), and inorganic polymers such as polyoxometalates
(15,16). The primary drug binding sites on the protein have
been mapped by structural studies (17,18). Recently, studies
have been conducted on the binding of organic contaminants
or toxins to HSA, e.g., arazine (19), ochratoxin (20), methyl
parathion (21), and arsenic (22). These compounds often
cause conformational changes in the protein, e.g., decrease in
a-helix and increase of b-sheet content. These studies showed
that the protein binds ligands selectively and covalently: few
ligand molecules bind, with a high heat of reaction. In fact,
the binding of any substance is likely to affect the activity of
the protein, either enhancing it (23) with potential medical sig-
niﬁcance or inhibiting it (24) if an organic contaminant or toxin
is involved.
Azo pigments are a structurally diverse and widely distrib-
uted group of synthetic compounds that include environ-
mental pollutants. Representatives of this group, poncean S
(PS) and its homologs discovered by Baurm (25), are used as
food additives and sometimes as cosmetic pigments and
biological stains, usually very effectively. PS can enter the
gastrointestinal tract via food intake or permeate into the
blood via skin absorption. As an azo compound, it can be
reduced by azo reductases to produce aromatic amines, some
of which are known carcinogens (26). Long-time use has
negative effects on human and animal liver, possibly result-
ing in degenerative pathological changes and cirrhosis (27).
pH varies widely among normal human body ﬂuids, for
example, a pH of,2 in gastric ﬂuid, pH 4–7 in sweat, pH 4.5
in vaginal ﬂuid, pH 5–7 in urine, and;pH 7.4 in blood. Any
compound that binds to a protein, enzyme, gene, or other
biomacromolecule will affect its structure and function to a
greater or lesser extent. For example, a drug binding to HSA
in the blood may be transported to the focus of disease for
therapeutic effect, but binding of a toxin may impede the
transport of endogenous substances.
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Ligand binding to macromolecules has previously been
studied by methods such as equilibrium dialysis (28), elec-
trochemistry (29), calorimetery (30), spectrophotometry (31),
and ﬂuorescence spectroscopy (32). In this work, isothermal
titration calorimetry (ITC), ultraviolet (UV), and circular
dichroism (CD) were used to characterize the binding of PS
to HSA at pH 1.81, 3.56, and 7.40, and the spectral cor-
rection technique (33), and the Langmuir and Temkin iso-
thermal models were used to elucidate the mechanism of
interaction. The interaction of PS with HSA was investigated
and compared in detail not only at room temperature but also
under normal physiological conditions: 0.8%–0.9% electro-
lyte, 37C. The various methods yielded highly consistent
results concerning, e.g., the saturation binding number of PS,
the binding energy of the reaction, and the bonds involved.
Ion pair electrostatic attraction (34) ﬁxes the position of PS in
HSA and subsequently induces the formation of a combi-
nation of other noncovalent bonds: H-bonds (35,36), hydro-
phobic interactions, and van der Waals forces. The type and
site of binding and the noncovalent bonds involved were
provisionally identiﬁed. Possible conformational change of
HSA in the presence of PS was also identiﬁed.
MATERIALS AND METHODS
Instruments and materials
The absorption spectra of PS and protein solutions were recorded with a
Model Lambda-25 spectrophotometer (Perkin-Elmer, Foster City, CA)
equipped with a thermostatic cell holder linked to a Model TS-030 water-
circulated thermostatic oven (Yiheng Sci. Technol., Shanghai, China). The
spectrophotometer was computer-controlled using UV WinLab software
(Version 2.85.04). The ITC experiments were carried out on a Model MSC-
ITC system (MicroCal, Studio City, CA) with measurement software. A
Model J-715 CD spectropolarimeter (Jasco Instruments, Tokyo, Japan) with
secondary structure estimation-standard analysis measurement software
(715 /No. B014460524, Jasco) was used to determine protein conformation.
A Model DK-8D electrothermic multiporous constant temperature (Shanghai
Yiheng Technol., Shanghai, China) was used in the temperature experiment.
Solution pHs were measured with a Model pHS-25 acidity meter (Shanghai
Precise Sci. Instrum., Shanghai, China).
HSA (250 mg, purity 96%–99%, Sigma Reagents, St. Louis, MO) was
dissolved in 250 ml deionized water as a stock solution (1.00 mg/ml HSA).
Solutions (0.010 mg/ml HSA) were prepared daily by diluting the stock and
were stored at 2C–8C. PS stock solution (0.750 mmol/l) was prepared by
dissolving 76 mg of PS (purity 75%, Shanghai Chemical Reagents, Chin.
Med. Group, Shanghai, China) in 100 ml deionized water. Solutions of
0.075 mmol/l PS were prepared daily by diluting the stock. A series of
Britton-Robinson (B-R) buffers, pH 1.81, 2.43, 2.97, 3.56, 4.19, 4.97, 5.43,
5.71, 6.38, 6.77, and 7.40, were prepared to adjust the acidities of solutions.
A 2.0 mol/l NaCl solution was prepared in deionized water to adjust the
ionic strengths of solutions to investigate the effects of electrolyte on non-
covalent binding. Both 0.01 mol/l EDTA and pH 3.6 acetic-acetate buffer
were prepared and used only in protein assays.
Photometric determination of the
PS-HSA interaction
All studies were carried out in a 10.0 ml calibrated ﬂask containing a known
volume of HSA solution, 2.0 ml of B-R buffer (pH 1.81, 3.56, or 7.40), and a
known volume of 0.750 mmol/l PS. The solution was diluted to 10.0 ml with
deionized water and mixed thoroughly. After the reaction had proceeded for
5 min, the absorbances Al2 and Al1 of the HSA-PS solutions and A
0
l2 and
A0l1 of the reagent blank (without HSA) were measured at 568 nm (l2) and
495 nm (l1) against water. The parameters Ac, f, and g of each solution were
calculated. The Langmuir and Temkin isothermal models were applied to ﬁt
plots g1 vs. C1L and g vs. ln(CL). Finally, N, K, and DQ were calculated.
Thermodynamic characterization of the PS-HSA
interaction by ITC
ITC experiments were carried out as follows. The PS solution (0.600 mmol/l
in pH 1.81 and 3.56 B-R buffers or 0.300 mmol/l in pH 7.40 B-R buffer) was
injected ;40 times in 5 ml increments at 3 min intervals into the isothermal
cell containing HSA (1.6 mmol/l in pH 1.81 and 3.56 B-R buffers or 8.0
mmol/l in pH 7.40 B-R buffer). The cell temperature remained at 25C or
37C. Heats of dilution of PS, obtained separately by injecting into the
buffer, were used to correct the data. The corrected heats were divided by the
number of moles injected and analyzed using the Origin software (version
7.0) supplied by the manufacturer. The titration curve was ﬁtted by a non-
linear least squares method and N, Kb, DH, and DS were determined.
CD measurement of HSA conformation in the
presence of PS
Buffer (1 ml, pH 1.81, 3.56, or 7.40) was mixed with 0.030 mg/ml HSA in
three ﬂasks; 0, 0.015 or 0.060 mmol/l PS was added. The solutions were
diluted to 10.0 ml with deionized water. Simultaneously, a reagent blank
without PS was prepared. Before measurement, all the solutions were diluted
from 1.00 to 3.00 ml with deionized water. Each sample was allowed to
equilibrate for 15 min, then injected into a 0.1 cm light path cell, and the
mean residue ellipticity (MRE) of HSAwas measured between 200 and 250 nm.
From the MRE curves, the relative contents of secondary structure forms of
HSA—a-helix, b-pleated sheet, b-turn, and random coil—were calculated
in all the solutions.
Protein assay
Light-absorption ratio variation (LARVA) (37) was used to assay protein
with very high sensitivity. A known volume of a sample containing,70 mg
of protein was added to a 10 ml ﬂask along with 1 ml 10 mmol/l EDTA and
1 ml of pH 3.6 acetate buffer. After mixing, 3.0 mmol/l PS was added and the
solution was diluted to 10.0 ml with deionized water. After 5 min, the ab-
sorbances (A495 and A568) of the solution were measured at 495 and 568 nm
against water. Using the same method, a reagent blank without protein was
prepared, and the absorbances (A0495 and A
0
568) were measured. The absorbance
ratio difference (DAr) of the PS-HSA solution was calculated by the relationship
DAr ¼ A568nm
A495nm
 A
0
568nm
A
0
495nm
: (1)
DAr is linearly related to the protein concentration (CM0) as follows:
DAr ¼ pCM0 1 q; (2)
where p and q are constants obtained by linear regression of plots of DAr vs.
CM0 from the series of standard HSA solutions. The variable p as the sen-
sitivity factor is inversely proportional to the initial concentration (CL0) of
ligand (37): the less L added, the higher the sensitivity obtained. However,
too low a PS concentration will cause an obvious measurement error because
of background instrument noise. To optimize the addition, PS was added in
three concentrations (1.5, 3.0, and 4.5 mmol/l) to the series of standard HSA
solutions and the DAr of each was calculated. By considering both the low
limit of detection (LOD) and the linearity, an optimal PS concentration was
selected.
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RESULTS AND DISCUSSION
Effect of pH on the PS-HSA interaction
Fig. 1 illustrates the color change of PS solution in the presence
of HSA and also shows the chemical structure of PS. PS is an
orange anionic azo compound in aqueous solution 1, and it
reacts with HSA to form a red product in solution 2. The
absorption spectrum of the product shows a marked red shift.
HSA-PS solutions were measured in various pH media, and
their absorption spectra are shown in Fig. 2 A. The interval
between the positive peak and the negative trough increases
with increasing acidity of solution. From curves 1–4, the peak
valley interval changes little when the pH is below 3.56. Given
the dissociation constants (KR) of the side groups (R) of basic
and acidic amino acid residues (AARs) (10.53 for Lys, 6.00 for
His, 12.48 forArg, 3.65 forAsp, and 4.25 forGlu), noR groups
will have a negative chargewhen the pH is,3.65, whereas the
Rs of the basic AARs will be positively charged.
PS anions will enter the HSA cleft with no charge repul-
sion. However, there are 98 negatively charged acidic AARs
in HSA, together with 98 positively charged basic AARs when
the pH is .4.25. Entry of PS will therefore be opposed by
charge repulsion. Therefore, from curves 6–11, the binding of
PS to HSA becomes progressively weaker. The two troughs in
each curve indicate that PS-HSA binding is heterogeneous at
any pH, i.e., there is a mixture of complexes linked via two,
three, and four sulfonate groups because the PS concentration
is not high enough. To compare the interactions of PS with
HSA in various pH media including that of normal blood, i.e.,
pH 7.40, three buffer solutions, pH 1.81, 3.56, and 7.40, were
used. From curves 1, 4, and 11 in A, 568 (l2) and 495 nm (l1)
were the wavelengths that most clearly indicated the binding
process and were used in subsequent work.
From the absorption spectra shown in Fig. 2 B, it is apparent
that formation of the PS-HSA complex resulted in red shifts:
from 497 to 565 nm (curve 1) at pH 1.81 and from 500 to 566
nm (curves 2 and 3) at pH 3.56 and 7.40. Interestingly, a sec-
ondary trough appears at 528 nm only in curve 1. A possible
reason is that the unfolding of HSA at pH 1.81 increases the
distances among positively charged AARs. The dissociation
constants (Ka) of PS (L) were also determined spectrophoto-
metrically (38), and the results indicated that pKa is between 2
and 3 for H2L
3 and more than 9 for HL4. Therefore, H2L
3
and HL4 were both present in the pH 1.81 solution, leading
to three and four ionic bonds between HSA and each PS
molecule. Thus, PS-HSA binding is heterogeneous at pH 1.81
even if there is sufﬁcient PS in solution to achieve saturation.
Photometric characterization of the
PS-HSA interaction
The interactionofPS(L)withHSA(M) is summarizedas follows:
NPS 1 HSA
Kb
HSAðPSÞN
Initiation CL0ðA0l2Þ CM0 0
Equilibrium CL ¼ CL0  NCM0ðAl1;Al2Þ CM/0 CM0ðACÞ
From the color change in Fig. 1, it is clear that to deter-
mine the absorbance of the PS-HSA complex in solution 3,
FIGURE 1 Cartoon illustrating the color change in the HSA-PS reaction:
(1) PS solution; (2) HSA-PS solution containing excess HSA in which free
PS approached zero; (3) As 2, but containing micro amounts of HSA.
Solution 3 consists of solutions 4 and 5, which were actually nonmeasurable.
FIGURE 2 (A) Absorption spectra, measured against the reagent blank, of
HSA-PS solutions containing 7.5 mmol/l PS and 50.0 mg/l HSA at pH
values (1–11): 1.81, 2.43, 2.97, 3.56, 4.19, 4.97, 5.43, 5.71, 6.38, 6.77, and
7.40. (B) Absorption spectra of the solutions containing 7.5 mmol/l PS and
0.80 mg/ml HSA at pH 1.81 (1), 3.56 (2), and 7.40 (3) against water. There
was no free PS because the solutions contained excess HSA.
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interference by excess PS in solution 4 must be eliminated.
The spectral correction technique (33) proposed previously
is a useful method for this; it involves measuring solutions 1,
2, and 3. The effective fraction (f) of PS bound to HSA and
the molar ratio (g) of PS bound to HSA are calculated by the
relationships (39)
f ¼ Ac  Al2
A
0
l2
1 1 (3)
and
g ¼ f 3 CL0
CM0
; (4)
where
Ac ¼ Al2  bAl1
1 ab : (5)
Returning to the reaction equation above, CM0 and CL0 are
the initial molar concentrations of HSA and PS; Ac indicates
the real absorbance of the HSA-PS complex in solution 3 at
568 nm, which cannot be measured directly. Al2 and Al1 are
the absorbances of the HSA-PS solution 3 measured at 568
and 495 nm, respectively, against water; a and b are correc-
tion constants and were calculated by measuring solutions 2
and 1 shown in Fig. 1. The g value will approach the satura-
tion number (N) of PS bound with the increase of PS in a
HSA solution.
The absorbance ratios of the HSA-PS solutions were mea-
sured at 495 and 568 nm (Fig. 3 A). The A495/A568 ratios in
three pH media all decrease with increasing HSA concen-
tration and approach a constant value of 1.6 when the molar
concentration of HSA is more than 1.2 times that of PS. This
indicates that more and more PS molecules became bound to
HSA until no excess PS was free in solution, i.e., solution 2
in Fig. 1. Thus, the constant minimum should be a of the
binding product; the b values of PS in various media corre-
spond to the A568/A495 ratio in the absence of HSA, which are
located at the beginnings of curves 1–3. By measuring a
series of PS solutions containing known concentrations of
HSA, Ac, f, and g were calculated using Eqs. 4–6. The vari-
ation in g with PS is shown in Fig. 3 B; the value increases
with increasing PS concentration. Moreover, the values
approach the following maxima: 30 when the PS/HSA molar
ratio is more than 30 (from curve 1), 25 when the ratio is
more than 25 (from curve 2), and 1.7 when the ratio is more
than 5 (from curve 3).
These results indicate that the binding of PS to HSA is
saturable. When more PS is added, the fraction of excess PS
steadily increases, but g does not change. Thus, N of PS
molecules bound per molecule of HSA are ;30 at pH 1.81,
;25 at pH 3.56, and ;1.7 at pH 7.40. These values will be
examined further in the following experiments. As described
above, all the basic AARs in HSA form positively charged R
groups in pH solution of ,3.65, whereas all acidic AARs
will not dissociate. Thus, PS anions bind easily to the HSA
surface until saturation is reached. In contrast, negative R
groups of the acidic AARs rejecting the concentration of PS
ions increases when pH is .4.25. Therefore, N of PS at pH
7.40 is much less than those in acidic media. The Langmuir
and Temkin isothermal models (40) below were used to ﬁt
the experimental data.
1
g
¼ 1
N
1
1
KNCL
(6)
and
FIGURE 3 (A) Variation of the absorbance ratio
(A495/A568) of solutions containing 7.5 mmol/l PS and
00.80 mg/ml HSA. (B) Variation of g in solutions
containing 50.0 mg/l HSA and variable PS. (1) pH
1.81, (2) pH 3.56, and (3) pH 7.40.
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g ¼ NRT
DQ
lnðCLÞ1 a; (7)
where CL is the equilibrium concentration of PS to be calcu-
lated by CL ¼ (1  f)CL0, K is the adsorption constant, and
DQ the adsorption energy (J/mol) of a saturating concentra-
tion of PS. The term a is a regression constant, T the tem-
perature in degrees Kelvin, and R the gas constant, 8.314 J
mol1 K1. The results are given in Fig. 4. The binding of PS
to HSA ﬁtted both models when the number of PS molecules
per HSA molecule was less than the maximal binding
number. Therefore, the interaction of PS with HSA corre-
sponds to chemical monolayer adsorption. From the inter-
cepts and gradients of the regression lines in Fig. 4 A, both N
and K of PS may be calculated (Table 1). The N values were
consistent with those obtained from Fig. 3. DQ of PS was
calculated from the line gradients in Fig. 4 B, as shown in
Table 1. The increase in K and DQ values with increase in pH
shows that PS binds more stably in neutral solution. A pos-
sible reason is that a low PS binding number resulted in more
binding sites on HSA. In addition, the binding of PS is exo-
thermic because of the negative heat of adsorption.
ITC characterization of the PS-HSA interaction
To understand the mechanism of HSA-PS binding and to
assess the effect of environmental conditions, e.g., acidity,
on its speciﬁcity and stability, detailed thermodynamic data
are needed. ITC measurements provide information on ther-
modynamic quantities such as enthalpy and heat capacity
changes during the molecular interaction directly from the
heat produced by the reaction and have been used to study,
for example, protein-ligand interactions (41), DNA triplex
formation (42), and human immunodeﬁciency virus (HIV)
protease activity (43). Fig. 5 (X-1) (X: A–D) depicts a typical
isothermal titration proﬁle obtained by injecting PS into the
ITC cell containing HSA. An exothermic heat pulse is
detected after each injection; its magnitude progressively
decreases until a plateau is reached corresponding to the heat
of dilution of the peptide species in the buffer and indicating
saturation. The heat evolved at each injection was corrected
for the heat of dilution, which was determined separately by
injecting the PS solution into the buffer and divided by the
number of moles injected. The resulting values were plotted
as a function of the PS/HSA molar ratio and ﬁtted to a sig-
moid curve by a nonlinear least squares method (curves X-2
in Fig. 5). Values for the equilibrium binding constant (Kb),
binding number (N), enthalpy change (DH), and entropy
change (DS) of the PS-HSA reaction at various pHs were
obtained from curves X-2 and calculated by the Gibbs free
energy (DG) equation:
DG ¼ RT lnKb ¼ DH  TDS: (8)
The thermodynamic parameters derived from these curves
are summarized in Table 1. Comparison with the photomet-
ric method (above) shows that the three measurements yield
similar N values at three pHs. DH and DQ both become
increasingly negative with increasing pH at 25C, and DQ
approaches the DH value at the same pH. Therefore, the
Temkin isothermal model can be used to explain the binding
mechanism. Because DH is much less than 60 kcal/mol (44),
the PS-HSA interaction is noncovalent: it involves H-bonds,
ion pair attraction, hydrophobic interactions, and van der
Waals forces. The Kb values indicate that the complex
becomes more stable with increasing acidity of solution. This
can be explained by the tendency of DG to decrease with
increasing pH (Table 1 and Fig. 6). Comparison of the DG,
DH, and TDS values suggests that the PS-HSA interaction
is amphipathic and H-bonds and ion pair binding are both
major contributors, i.e., the interaction of PS with HSA de-
pends on a combination of ion pair attraction and H-bonds.
Moreover, the heat released during the PS-HSA reaction
increases with increasing pH, i.e., the ion pair attraction and
FIGURE 4 Plots of (A) g1 vs. CL
1 and (B) g vs.
ln(CL) from solutions containing 50.0 mg/l HSA and
variable PS. (1) pH 1.81, (2) pH 3.56, and (3) pH 7.40.
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H-bonds between PS and HSA are weakened in more acidic
solution. This indicates that the number of H-bonds formed
by PS is lower in more acidic solutions.
As described above, the unfolding of HSA at pH 1.81
increases the distance among positively charged AARs. In
contrast, DS becomes more negative with increasing pH.
This indicates that PS binding destroyed the internal hydro-
phobic interactions in HSA at pH values above 3.56, re-
placing them with ion pair attraction and H-bonds. The
chemical structure of PS shows that all the aryls are enclosed
by hydrophilic groups (SO3, N¼N, and OH), and
PS has no lipophilic substituent, e.g., the halogen or alkyl
group. Thus, hydrophobic interactions between PS and HSA
were probably weaker than the internal ones in HSA. On the
other hand, PS binding could have induced folding of HSA,
decreasing the entropy. In addition, comparison of the ther-
modynamic parameters of the solution between 37C and
25C at pH 7.40 shows thatDH becomes more positive but
DS becomes more negative (Table 1 and Fig. 6). This indi-
cates that ion pair attraction and H-bonds were strengthened,
but hydrophobic interaction was weakened at normal phys-
iological pH.
Fixing of the position of PS by ion pair
attraction induces the formation of a
combination of multiple bonds
Electrostatic forces have an important role in the binding of
ligands to proteins (16), especially in acidic media. However,
the relationship between the number of anionic groups on a
ligand and the number of basic AARs on a protein has not yet
been determined. From f ¼ N/Nb, the effective binding rate
(f) of PS to HSA can be calculated, where Nb is the total
number of protonated basic AARs of HSA (Lys, His, and
Arg). The dissociation constants of the R groups of Lys, His,
and Arg indicate that they are all positively charged when the
pH is ,6. However, only the R groups of Lys and Arg
residues are protonated in neutral medium. Thus, Nb is 98 in
acidic solution and 79 in neutral solution.
TABLE 1 Determination of the thermodynamic parameters of the HSA-PS binding reaction at pH 1.81, 3.56, and 7.40 at 25C
pH N* K*, 3106 M1 DQy, kcal/mol Nz Kb
z, 3106 M1 DH z, kcal/mol DSz, (cal/mol)K1 DG§, kcal/mol
1.81 31 1.51 9.33 29.4 5.93 7.95 4.34 9.23
3.56 26 1.39 11.0 23.3 1.12 9.02 2.59 8.25
7.40 1.7 2.88 12.4 1.56 0.78 10.9 9.58 8.04
7.40{ / / / 1.43 0.30 11.2 11.2 7.73
*By the Langmuir adsorption isothermal.
yBy the Temkin adsorption model.
zBy ITC.
§Calculated by Eq. 8.
{At 37C.
FIGURE 5 X-1 (X¼ A, B, C, andD): ITC titration proﬁle of PS-HSA binding at (A) pH 1.81, (B) pH 3.56, and (C andD) pH 7.40. The temperature was 25C
(A–C) or 37C (D). Each pulse corresponds to a 5-ml injection of (A and B) 0.600 mmol/l PS or (C and D) 0.300 mmol/l PS into the ITC cell (1.4685 ml)
containing (A and B) 1.6 mmol/l HSA or (C and D) 8.0 mmol/l HSA. X-2. The area of each peak in X-1 was integrated and corrected for the heat of dilution,
which was estimated by a separate experiment by injecting the PS into the B-R buffer. The corrected heat was divided by the moles of injectant, and values were
plotted as a function of the PS/HSA molar ratio. The titration curve was ﬁtted by a nonlinear least squares method.
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In a more acidic solution, the peptide chain of a protein
unfolds (16), and there is little steric hindrance. If the binding
of PS to HSA depended only on ion pair attraction, f should
approach 100%. From the N values obtained above, f of PS
was calculated to be 31% at pH 1.81, 27% at pH 3.56, and
2.2% at pH 7.40. Because each PS molecule has four sulfo-
nate groups, it can bind to at most four basic AARs, so all the
basic AARs in HSA could bind to PS at pH 1.81 and 3.56.
However, most of the PS molecules bound to the peptide
chain via three sulfonates, i.e., three ionic bonds, at pH 1.81,
whereas most of them bound via four sulfonates at pH 3.56.
HSA tends to fold at pH 7.40, so steric hindrance increases,
leading to a marked decrease of f even though PS may still
bind via four ionic bonds. From the number of bonds formed
by PS, the PS-HSA binding energy is low at pH 1.81, as
conﬁrmed by the DH values above. In conclusion, ion pair
attraction could have induced PS to enter the cleft of HSA,
i.e., electrostatic attraction plays a position-ﬁxing role in the
interaction of the small ligand with the protein.
Once the PS molecules are positioned in HSA, other non-
covalent bonds—H-bonds, hydrophobic interactions, and
van der Waals forces—could act in combination. PS contains
other potential binding groups in addition to the negatively
charged SO3 groups, e.g., N¼N and OH, which
could form H-bonds with polar side groups of AARs in the
peptide chain, but there will be little hydrophobic interaction
between PS and HSA, as described above. An illustration of
PS bound to the peptide chain in acidic solution is shown in
Fig. 7. Thus, the combined action of noncovalent bonds will
bind the small ligand ﬁrmly. As an example, the side group
of K195 in the IIA domain and those of K446 and H464 in
the IIIA domain would ﬁx PS by ion pair bonds, and then the
side groups of S193, Q198, and E465 would bind the PS by
H-bonds. In a neutral solution, pH 7.40, the negative R
groups of Asp and Glu, which are distributed throughout the
peptide chain, will exclude the entry of PS anions even
though the positive Rs of Lys and Arg residues attract them.
Possibly only two spatial positions can be occupied by the
PS anion, i.e., between K212–R218 and R348–K351, K402–
R410 and R428–K432, which have no negative R groups
around them. This is consistent with the number of PS mol-
ecules bound at pH 7.40.
Effects of electrolyte, temperature, and in situ
pH change
The stability of a noncovalent complex is always affected
by properties of the liquid environment in the body such as
pH, ionic strength, and temperature (45,46). The effect of
FIGURE 6 Comparative distribution ofDH (left column) and TDS (middle
column) in DG (right column) at pH 1.81 (25C), 3.56 (25C), and 7.40
(25C and 37C).
FIGURE 7 Cartoon illustrating the possible binding sites of PS in HSA and the corresponding bonds. (A) HSA single chain; red line represents positively
charged amino acid residues. (B) As an example, PS is inserted between two a-helices (one from S192 to R197 in the IIA domain, and the other in green from
V462 to P468 in the IIIA domain), replacing the original internal noncovalent bonds and forming ion pair bonds (green concave-convex rectangle), H-bonds
(yellow rounded rectangle), and possibly hydrophobic interactions (red ellipse). (C) Cartoon illustrating how the secondary structure of HSA changed from
b-sheet to helix (PS binding with the side groups (Rs) on lines 2 and 3) and turn (PS binding with the Rs on line 1 only) in PS solution. Lines 1, 2, and 3: peptide
chain, and Rank A-P: AAR sequence.
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electrolytes on the g value of PS in the HSA-PS interaction is
shown in Fig. 8 A. With increasing electrolyte concentration,
g decreases in various pH media and the change from curve
3 was most evident at pH 7.40. Its value in 1.0 mol/l elec-
trolyte is 70% that in the absence of electrolyte at pH 1.81
and pH 3.56, but only 25% at pH 7.40. This is due to the
Debye-Huckel screening, where the Debye length is in-
versely proportional to the square root of the ionic strength of
solution (47). Human blood normally contains ;0.15 mol/l
electrolyte. From all curves in A, g is only slightly different
in such a solution from g in the absence of electrolyte. This
implies that the ions in body ﬂuids would not affect PS
binding. When the ion concentration is increased to .0.5
mol/l, the marked adsorption of PS suggests that such con-
ditions could be favorable for transmission of endogenous
substances and drugs.
At higher temperature, the protein cleft expands, increas-
ing the distance between the adjacent peptide chains. Thus,
the effective number of ligand binding sites is reduced, often
causing desorption of ligand from the protein (48). However,
the interaction of PS with HSA seems contradictory. At pH
7.4, g decreases from curve 3 in Fig. 8 B, especially when the
temperature is .40C. At 37C, g decreases to ;1.7 from
;1.9 at room temperature. In contrast, curves 1 and 2 indi-
cate that g increases slightly with warming. A PS-HSA com-
plex with a high binding number would form aggregates
so that the PS would be physically adsorbed on the particle
surfaces.
The slightness of the effects of ionic strength ,0.2 mol/l
and temperature ,40C indicates that PS binds strongly to
HSA although the interaction is noncovalent. Thus, the
penetration of PS-like organic structures into the blood could
inhibit the endogenous transport of drugs. To investigate the
stability of the product with the highest PS binding number
at pH 1.81, a PS-HSA solution prepared at pH 1.81 was
measured and then the pH was adjusted in situ step-by-step
with 1 mol/l and 0.1 mol/l NaOH from pH 1.81 to 7.40. g
was calculated at each pH by Eq. 4, and its variation is shown
in Fig. 8 C. The g values in two such solutions, containing
saturating (solution 1) and semisaturating (solution 2) con-
centrations of PS, approach those in Fig. 3 B obtained from
PS-HSA solutions prepared independently at pH 3.56 and
7.40. Moreover, g decreases markedly when the pH exceeds
the isoelectric point of HSA. This is attributed to the un-
folding of HSA in acidic media and the protonation of basic
AARs, which is less at pH values above 4.7. In addition, the
PS-HSA complex formed at pH 1.81 can be destroyed
by low pH, as indicated by the trend in g, i.e., binding to HSA
is reversible and has not caused permanent denaturation.
Effect of PS on the secondary structure of HSA
The speciﬁc conformation of a protein with a particular func-
tion results from covalent and noncovalent interactions among
its amino acid residues. When an organic compound such as a
pollutant, drug, or toxin is added to a protein solution, the
internal noncovalent interactions of the peptide chain may be
altered and possibly destroyed, changing the original confor-
mation. In particular, strong binding between a protein and an
organic ligand may cause a permanent and irreversible change
in the conformation and loss of the original function. CD spec-
trometry is often used to evaluate the secondary structure of a
protein, i.e., the contents of b-pleated sheet, b-turn, a-helix,
and random coil. The molar ellipticity CD curves of the PS-
HSA solutions in various pH media are shown in Fig. 9, and
the analytical results are summarized in Table 2.
The b-sheet content of HSA decreased to 0 at pH 1.81 and
3.56 with less than saturating concentrations of PS (15mmol/l),
FIGURE 8 Effects of (A) electrolyte, (B) temperature, and (C) pH on g of solutions. Both A and B contained 0.030 mmol/l PS and 50.0 mg/l HSA (1 and 2) or
200 mg/l HSA (3) at (1) pH 1.81, (2) pH 3.56, and (3) pH 7.40. (C) The pH of the solution (25 ml) was adjusted in situ step-by-step with 1 mol/l and 0.1 mol/l
NaOH, where solution 1 contained 60.0 mg/l HSA and 0.015 mmol/l PS and solution 2 contained 60.0 mg/l HSA and 0.060 mmol/l PS.
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where ;80% of all available binding sites in HSA were
bound by PS. The disappearance of b-sheet resulted in a
marked increase in b-turn content, for example, from 4.3% at
pH 1.81 and 5.8% at pH 3.56 to 30.1% and 30.7%.
Moreover, the helix content increased by ;20%. Compar-
ison between saturating and subsaturating concentrations of
PS produced no obvious change in secondary structure
contents though 4 times the molarity of PS was added. Thus,
a small amount of PS leads to a marked change of protein
conformation in acidic media. Fig. 7 C illustrates how the
binding may affect changes from b-pleated sheet to helix and
turn. On a single peptide chain (chain 1), PS could bridge the
side groups (Rs) CA1 (rank A and line 1) and CG1 by ion pair
attraction.
Thus, both the A–C and E–G sector sheets would rotate
inversely around CD1 to split the original H-bonds between
chains 1 and 2, leading to formation of an H-bond between
C¼O (E1) and NH (C1). Thus, the pleated sheet is changed
into a turn. If both Rs were located on chains 2 and 3, such as
CG2 and CM3, respectively, ion pair attraction would draw
both of them close to the two available SO3 groups of PS
by inverse rotation. Because of the perturbation caused by
PS, the original H-bonds between chains 2 and 3 would be
destroyed and a new H-bond betweenNH (I3) andOH of
PS formed. Therefore, the b-sheet was changed into helix. In
contrast, all the secondary conformational factors changed
little at pH 7.40 even with saturating PS concentrations. This
is presumably because there is too little binding of PS at pH
7.40 to affect the conformation of HSA markedly. As a
deduction, the binding of PS to proteins or enzymes in acidic
environments, e.g., stomach and skin secretions, might
produce obvious toxicity. In normal blood, the tight binding
of PS to HSA would inhibit the transmission of endogenous
substances and drugs, though the secondary conformation of
HSA would not be markedly altered.
Application of the interaction to protein assay
Calibration graphs and LOD
The characterization of the binding reaction and the effects
of electrolyte and pH described above indicate that the
interaction between PS and HSA is inﬂuenced by a range of
experimental conditions such as ionic strength ,0.2 mol/l,
pH between 2 and 4, and temperature ,40C. Thus, it may
be used for protein assay by LARVA (37), which has more
than 10 times the analytical sensitivity of ordinary spectro-
photometry. If EDTA is added to sequester most metal ions,
this binding reaction is very selective. Three standard series
of HSA were prepared, and the regression equations are
given in Table 3. The LOD of HSA, deﬁned as 3 times the
standard deviation of 10 replicated blanks, was also calcu-
lated and is given in Table 3: the less PS added, the higher
the sensitivity obtained. However, too low a PS concentra-
tion could cause an obvious measurement error because of
background instrument noise. The LODs of series 2 and 3 are
the lowest, but series 2 gives the best linearity. Thus, 3.0
mmol/l PS was added to determine the protein concentrations
in samples such as food and blood. The corresponding LOD
of protein is 0.2 mg/l.
Effect of foreign substances
EDTA was used to sequester most of the metals that might
occur in the samples. The results indicate that none of the
following species affected the direct determination of 5.0
mg/l HSA (error less than 65%) with PS: 100 mg/l lysine,
glutamine, alanine; 100 mg/l K1, Cl; 5.0 mg/l Ca21, PO4
3,
glucose; 2 mg/l Mg21, SO4
2, vitamin C; 1 mg/l Zn21, Fe21,
Fe31; and 0.2 mg/l Cu21. Therefore, the recommended method
was selective and suitable for quantitative analysis of water-
soluble proteins.
FIGURE 9 The molar ellipticity CD curves for HSA (0.030 mg/ml)
solutions at (A) pH 1.81, (B) pH 3.56, and (C) pH 7.40, containing PS: (1) 0,
(2) 0.015, and (3) 0.060 mmol/l in both A and B and (1) 0, (2) 0.56, and (3)
2.25 mmol/l in C.
TABLE 2 Variation of the secondary conformational factors of
HSA in the presence of PS in various pH media
pH Factor
Rate, %
no PS 0.015 mmol/l 0.060 mmol/l PS
1.81 a-helix 29.3 35.6 39.1
b-sheet 35.2 0 0
Turn 4.3 30.1 32
Random coil 31.2 34.3 29
3.56 a-helix 37.8 42.4 45
b-sheet 28.6 0 0
Turn 5.8 30.7 31.5
Random coil 27.8 26.9 23.5
7.40 a-helix 32.2 34.1* 31.5y
b-sheet 26 16.5* 27.2y
Turn 16.4 20* 15.5y
Random coil 25.4 29.4* 25.8y
All of the solutions contained 0.030 mg/ml HSA.
*Contained 0.56 mmol/l PS.
y2.25 mmol/l PS.
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Analyses of samples
Five samples—quail egg white, milk, human blood, chicken
serum, and eel serum—were determined. Both quail egg
white and milk may be diluted and then colored directly. The
other samples were treated according to the following pro-
cedures: 5 ml blood extracted from human or animal veins
was centrifuged at 3000 rpm for 10 min and 1.00 ml of the
supernatant was diluted to 100 ml. After mixing, protein was
assayed. The results are given in Table 4. They agreed with
the values obtained by classical Coomassie brilliant blue
colorimetry (49). This indicates that the proposed method is
accurate and reliable for practical analysis.
CONCLUSIONS
Knowledge of biomolecular interactions such as protein-
protein (50) and protein-ligand binding, enzyme catalysis,
and inhibition is important for our understanding of cellular
processes including signal transduction, gene regulation, and
enzyme reactions (51). Such knowledge signiﬁcantly im-
proves our understanding of biological systems. More and
more studies of protein-ligand interactions have led to in-
creasingly widespread interest (52–54), where conventional
molecular spectrometric methods such as ﬂuorescent probe,
UV, and CD are most widely used. Recently, binding mech-
anisms have been studied intensively using x-ray crystal-
lography, NMR, ITC, and surface plasmon resonance
biosensors (55,56), which are powerful analytical tools in
enzymology, rational drug design, and toxicology. Ligand
binding is often associated with denaturation of macromol-
ecules (folding or unfolding).
Some modes of binding are exothermic (such as electro-
static interaction) and others are endothermic (such as
unfolding). Thus, the primary interactions are usually elec-
trostatic (16). The formation of covalent complexes with
speciﬁc residues in a protein is being studied increasingly in,
for example, aspects of DNA repair (57), identiﬁcation of
enzyme active sites (58), pharmaceutical development (59),
and heavy metal toxicity (60). However, noncovalent inter-
actions are more numerous in cells. Although a noncovalent
bond is often weaker than a covalent bond, the combination
of many noncovalent bonds will produce a stronger associ-
ation. This work proposed that electrostatic interaction
induced a combination of noncovalent bonds—H-bonds,
hydrophobic interactions, and van der Waals forces—which
was illustrated. In contrast to the binding of metal complexes
and pesticides (21), noncovalent binding of organic com-
pounds is unselective.
By characterizing the interaction of PS with HSA using
various instrumentations and isothermal models, highly con-
sistent results were obtained concerning, e.g., binding
number, binding energy, and type of binding. PS formed a
stable complex with HSA, and the combination of non-
covalent bonds caused a marked change in the secondary
conformation of HSA in acidic media. This is the ﬁrst change
process of this kind to be illustrated. The potentially toxic
effect of PS was analyzed by determining PS-HSA binding
under normal physiological conditions. The mechanism of
interaction with the protein is very complicated. Although
the crystal structures of a number of proteins have been
analyzed and possible binding regions identiﬁed (2), it has
not been possible to distinguish all the intermediate forms or
to determine single noncovalent bond energies accurately.
This work provides a useful experimental strategy for study-
ing the interaction of organic substances with biomacromol-
ecules. It helps us to understand the activity or mechanism of
toxicity of an organic compound.
We thank Dr. Shao-Feng Luo of Univ. Sci. Technol. China for his help with
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computer programs and data analysis.
We thank the Natural Science Foundation of China (Grant No. 20477030)
and the Shanghai Fundamental Research Project (Grant No. 04JC14072)
for ﬁnancially supporting this work.
TABLE 3 The linear regression equations at pH 3.6 for HSA assay and LOD of HSA
Series PS, mmol/l Linear scope of HSA, mg/l Regression equation R* sy LODz, mg/l
1 1.5 0–3.0 DAr ¼ 0.0491CM0 1 0.011 0.9867 0.0060 0.4
2 3.0 0–7.0 DAr ¼ 0.0354CM0 1 0.005 0.9980 0.0025 0.2
3 4.5 0–10.0 DAr ¼ 0.0237CM0  0.004 0.9969 0.0016 0.2
*Linear correlation coefﬁcient.
yStandard deviation of 10 replicated reagent blanks.
zLOD ¼ 3s/p (p-slope of line).
TABLE 4 Determination of proteins in samples with PS at
pH 3.60
Sample*
HSA
added,
mg
Proteins
foundy,
mg
Recovery,
%
Protein content
in sample,
mg/ml
Quail egg white 0 38.7 6 1.7 38.7
10 50.7, 48.4 120.1, 97.5
Fresh milk 0 58.3 6 0.6 58.3
10 69.8, 67.8 115, 95.2
Personal serum 0 20.1 6 1.5 20.1
10 31.2, 30.6 111, 105
Chicken serum 0 37.1 6 1.4 37.1
20 56.8, 57.7 98.7, 103.2
Eel serum 0 11.9 6 2.4 11.9
10 20.9, 22.3 90.0, 104.2
*0.100 mL of the diluted solution of a sample was added.
yAverage of four replicated determinations in a 10-ml colorimetric ﬂask.
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